Newsletter - January 4, 2024
FDA Released 21 New Guidance Documents in the Last 15 Days of 2023
It has become an annual ritual for FDA to release several new Guidance Documents in the last few days of a year and true to that, the FDA did exactly that by releasing 21 new Guidance Documents in the last 13 days of December. Many of these Guidance Documents affect critical aspects of FDA regulated...Read More
Compounding Pharmacies Fight the Stigma of Unapproved Drug Manufacturing
Last year’s biggest drug was semaglutide, the weight-loss drug marketed by Novo Nordisk as Wegovy and Ozempic. Both these drugs are currently in shortage which means that compounding pharmacies are allowed to compound them from active ingredients on prescription, and they have been. Novo pushed...Read More
FDA Released 21 New Guidance Documents in the Last 15 Days of 2023
It has become an annual ritual for FDA to release several new Guidance Documents in the last few days of a year and true to that, the FDA did exactly that by releasing 21 new Guidance Documents in the last 13 days of December. Many of these Guidance Documents affect critical aspects of FDA regulated...Read More
Compounding Pharmacies Fight the Stigma of Unapproved Drug Manufacturing
Last year’s biggest drug was semaglutide, the weight-loss drug marketed by Novo Nordisk as Wegovy and Ozempic. Both these drugs are currently in shortage which means that compounding pharmacies are allowed to compound them from active ingredients on prescription, and they have been. Novo pushed...Read More
